Affordable Access

Access to the full text

How can we consider variable RBE and LETd prediction during clinical practice? A pediatric case report at the Normandy Proton Therapy Centre using an independent dose engine

Authors
  • Mein, Stewart1, 2, 3, 4, 5
  • Kopp, Benedikt1, 2, 3, 4, 5, 6
  • Vela, Anthony7
  • Dutheil, Pauline7
  • Lesueur, Paul7, 8, 9
  • Stefan, Dinu7
  • Debus, Jürgen1, 2, 3, 4, 5
  • Haberer, Thomas5
  • Abdollahi, Amir1, 2, 3, 4, 5
  • Mairani, Andrea1, 5, 10
  • Tessonnier, Thomas1, 5, 7
  • 1 Heidelberg University Hospital, Heidelberg, Germany , Heidelberg (Germany)
  • 2 German Cancer Research Center (DKFZ), Heidelberg, Germany , Heidelberg (Germany)
  • 3 German Cancer Consortium (DKTK), Heidelberg, Germany , Heidelberg (Germany)
  • 4 Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany , Heidelberg (Germany)
  • 5 Heidelberg Ion-beam Therapy Center (HIT), In Neuenheimer Feld (INF) 450, Heidelberg, DE, 69120, Germany , Heidelberg (Germany)
  • 6 Heidelberg University, Heidelberg, Germany , Heidelberg (Germany)
  • 7 Centre François Baclesse, Caen, France , Caen (France)
  • 8 Centre Guillaume Le Conquérant, Le Havre, France , Le Havre (France)
  • 9 ISTCT UMR6030-CNRS, CEA, Université de Caen-Normandie, Equipe CERVOxy, Caen, France , Caen (France)
  • 10 National Centre of Oncological Hadrontherapy (CNAO), Medical Physics, Pavia, Italy , Pavia (Italy)
Type
Published Article
Journal
Radiation Oncology
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Feb 04, 2022
Volume
17
Issue
1
Identifiers
DOI: 10.1186/s13014-021-01960-w
Source
Springer Nature
Keywords
Disciplines
  • Radiation Physics
License
Green

Abstract

BackgroundTo develop an auxiliary GPU-accelerated proton therapy (PT) dose and LETd engine for the IBA Proteus®ONE PT system. A pediatric low-grade glioma case study is reported using FRoG during clinical practice, highlighting potential treatment planning insights using variable RBE dose (DvRBE) and LETd as indicators for clinical decision making in PT.MethodsThe physics engine for FRoG has been modified for compatibility with Proteus®ONE PT centers. Subsequently, FRoG was installed and commissioned at NPTC. Dosimetric validation was performed against measurements and the clinical TPS, RayStation (RS-MC). A head patient cohort previously treated at NPTC was collected and FRoG forward calculations were compared against RS-MC for evaluation of 3D-Γ analysis and dose volume histogram (DVH) results. Currently, treatment design at NPTC is supported with fast variable RBE and LETd calculation and is reported in a representative case for pediatric low-grade glioma.ResultsSimple dosimetric tests against measurements of iso-energy layers and spread-out Bragg Peaks in water verified accuracy of FRoG and RS-MC. Among the patient cohort, average 3D-Γ applying 2%/2 mm, 3%/1.5 mm and 5%/1 mm were > 97%. DVH metrics for targets and OARs between FRoG and RayStation were in good agreement, with ∆D50,CTV and ∆D2,OAR both ⪅1%. The pediatric case report demonstrated implications of different beam arrangements on DvRBE and LETd distributions. From initial planning in RayStation sharing identical optimization constraints, FRoG analysis led to plan selection of the most conservative approach, i.e., minimized DvRBE,max and LETd,max in OARs, to avoid optical system toxicity effects (i.e., vision loss).ConclusionAn auxiliary dose calculation system was successfully integrated into the clinical workflow at a Proteus®ONE IBA facility, in excellent agreement with measurements and RS-MC. FRoG may lead to further insight on DvRBE and LETd implications to help clinical decision making, better understand unexpected toxicities and establish novel clinical procedures with metrics currently absent from the standard clinical TPS.

Report this publication

Statistics

Seen <100 times